secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001493152-25-013074
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA reports positive THIO-101 Phase 2 data: PFS 5.6 mo, OS 17.8 mo in 3L NSCLC
-------------------------------------------------------------------------------

- Estimated median PFS of 5.6 months (180 mg dose) vs 2.5 months standard of care in third-line NSCLC.
- Estimated median OS of 17.8 months (95% CI lower bound 12.5 months), consistent with prior readout.
- 2 patients completed 33 cycles, suggesting extended dosing and tolerability for ateganosine.
- Phase 2 expansion trial began enrolling patients in July 2025 to further validate efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225013074/0001493152-25-013074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225013074/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-013074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer